John M. Evans, CEO at Beam Therapeutics Inc. (BEAM), sold 100,000 shares at $46.88 ($4.6M) on 2022-10-31, disclosed to the SEC on 2022-11-02.
Open-market sale of $4.6M BEAM by CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $44.92 | 7,567 | $340K | 7.3% |
| 2 | $44.92 | 7,567 | $340K | 7.3% |
| 3 | $44.93 | 5,008 | $225K | 4.9% |
| 4 | $44.93 | 5,008 | $225K | 4.9% |
| 5 | $46.19 | 4,569 | $211K | 4.6% |
| 6 | $46.19 | 4,569 |
| $211K |
| 4.6% |
| 7 | $46.19 | 7,768 | $359K | 7.7% |
| 8 | $46.19 | 7,768 | $359K | 7.7% |
| 9 | $46.88 | 11,756 | $551K | 11.9% |
| 10 | $46.88 | 11,756 | $551K | 11.9% |
| 11 | $46.91 | 8,235 | $386K | 8.3% |
| 12 | $46.91 | 8,235 | $386K | 8.3% |
| 13 | $47.89 | 2,909 | $139K | 3.0% |
| 14 | $47.89 | 2,909 | $139K | 3.0% |
| 15 | $47.91 | 2,188 | $105K | 2.3% |
| 16 | $47.91 | 2,188 | $105K | 2.3% |
| Total | $46.33 avg | 100,000 | $4.6M | 100% |
| Filing → |
| BEAM | SELL | 2026-04-01 | $1.1M | — | Filing → |
| BEAM | SELL | 2026-02-02 | $2.8M | — | Filing → |
| BEAM | SELL | 2025-10-03 | $1.2M | — | Filing → |